Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (March 2024)
87 slides from Perspective Therapeutics's investor presentation, Mar 8, 2024
Slide 1: Corporate Presentation
PERSPECTiVE THERAPEUTICS Corporate Presentation NYSE: CATX
Slide 2: Legal Disclaimers
Legal Disclaimers ‘Ts presentation cartans fomartoohing statements win the meaning ofthe United Sates Pate Secures Ligation Reform Act of 1995. Semen inthis pesetaton that are not Sotemerts of historical act are forwarcoatng statements. Words such as “may.” “wil” “sowd “expec.” “pan,” “anbepate” “co
Slide 3: Investment Highlights
Investment Highlights Platform radiopharmaceutical company targeting pan-cancer opportunities utilizing 2% generation «emitter
Slide 4: Platform Expansion Engine
Platform Expansion Engine ‘Two Lead Programs in Clinicand Broad Proprietary Pipeline VMTaneT vero vearo2 (PET agent) PSV369 (Novel peptie) PSVAOL Radios) Programs (Novel peptie) Pre-trgetng Pitt (tts) Other Programs (Nove! pepties) Neuroendocrine cancers Pheoctromocytomas, paragangliomas Small cel l
Slide 5: Pipeline With Multiple Expected Near-Term Data Readouts
Pipeline With Multiple Expected Near-Term Data Readouts
Slide 6: Management Team
Management Team Deep Experience in Radiopharmaceuticalsand Oncology Drug Development This Spoor Chief Execute Officer 20+ years of expertise in biotechnology ‘companies: publican private companies: ‘oncology and nucear pharmacy Jonathan Hunt Chie Financial Officer 20+ years of expertise in financial
Slide 7: Radiopharmaceuticals are a Pillar of Oncology Treatment
Radiopharmaceuticals are a Pillar of Oncology Treatment Unique Mechanism of Action Offers Pan-Cancer Opportunities Radloligands can precisely deliver radiation directly to cancer cells reducing offtarget effects Proven pillar of cancer treatment Porspectne's plain technology is optimized for greater
Slide 8: Perspective's Radiopharmaceutical Optimization Process
Perspective’s Radiopharmaceutical Optimization Process Unique Mechanism of Action Offers Pan-Cancer Opportunities Targeting Peptide Isotope Engineered for cance =Pb for SPECT imaging specific receptor sure high! 232pp for alpha particle therapy Linker Chelator
Slide 9: Lead-212: The Optimal Therapeutic Isotope
Lead-212 #2Pb): The Optimal Therapeutic Isotope Alpha Particles Provide Numerous Benefits Over Currently Used Beta Particle Radiotherapies ‘+ With a much higher atomic mass, alpha (a)particles generate more energy and travel a shorter distance compared to beta (B) particles, making them more cytotox
Slide 10: Chelator Optimized for Pb
Chelator Optimized for #7/2°3Pb Perspective’s Enabling Technology for Pb-based Radiopharmaceuticals . = ses a = + Designed spectticallyfor Pb isotopes HoN. + Optimized for rapid renal HO, NET2- ro NET2+ HO. Lo NETO. clearance through R R neutralized formal charge | S ‘+ Improves radiolabeling. 203pp
Slide 11: Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer
Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer Identical Distribution of Pb and “Pp for Imaging and Treatment, Respectively Cancer Cell Imaging =p Targeting ligand Linker Therapeutic Patient selection Dosimetry: T, , = 52h *pb can be used to establish Pb pharmacokinetic
Slide 12: Neuroendocrine Tumors: VMT-α-NET
Neuroendocrine Tumors: VMT-a-NET Targeting the somatostatin receptor to treat rare neuroendocrine- type cancers
Slide 13: VMT-α-NET Currently in Phase 1/2a Studies: Key Facts
VMT-c-NET Currently in Phase1/2a Studies: Key Facts Targeting somatostatin receptor type 2 (SSTR2) for the imaging and treatment of neuroendocrine tumors Initiated first-in-human imaging (2021) & therapy (2022) under compassionate use eived October 2022 Fast Track Designation for first line therapy
Slide 14: SSTR2 is an Attractive Target for Identifying and Treating Tumors
SSTR2 is an Attractive Target for Identifying and Treating Tumors Expressed Across Several Tumor Types. Neuroendocrine tumors (NETS) + Neuroendocrine cells are specialized cells that secrete hormones and other bioactive substances + Neuroendocrine cells are found throughout the body * Often grow in
Slide 15: Decreased Off Target Toxicity, Increased Tumor Uptake and Retention in Preclinical Studies
Decreased Off Target Toxicity, Increased Tumor Uptake and Retention in Preclinical Studies SSTR2 tumor model demonstrates superiority of VMT- «NET to generic compounds 8-fold improved tumor uptake with decreased kidney retention PERSPECTIVE
Slide 16: VMT-α-NET Shows Significant Improvement vs Standard of Care in Preclinical Models
VMT-o-NET Shows Significant Improvement vs Standard of Care in Preclinical Models ‘Superior Efficacy with Single Dose or Multiple Administrationsin AR42J SSTR2-Expressing Tumor 20 j> poronmraner (ie e=pbyMraNer (4x420 wey Ie. (4x30 nC) owes oot t + 18 | } DrapAdnnsteres Qs
Slide 17: 203Pb SPECT Imaging Reveals Favorable VMT-α-NET Properties
203Pbh SPECT Imaging Reveals Favorable VMT-o-NET Properties” Rapid Tumor Targeting, High Tumor and Renal Clearance Retention . Lhour 21 hours Tumors visible within 1 hour indicates rapid binding to SSTR2 target High intensity above background implies excellent therapeutic window Unbound drug in blad
Slide 18: Diagnostic and Therapeutic Show Same Uptake and Retention Characteristics
Diagnosticand Therapeutic Show Same Uptake and Retention Characteristics 15h SPECT/CT 22 hrs SPECT/CT PERSPECTIVE
Slide 19: Significant Response After Single Dose of VMT-α-NET
Significant Response After Single Dose of [72Pb]VMT-c-NET Metastatic NET Pancreas with Adrenal Crisis - Maximum Intensity Projection (MIP) Treatment ‘Tumor After 1 Dose + 8§Ga-DOTA-NOC PET images at base line and post 1st dose of (22Pb]VMT-o-NET + MIP suggesting strong reduction of intensity (thorac
Slide 20: Significant Response After Single Dose, Almost Complete Response After 3 Doses
Significant Response After Single Dose, Almost Complete Response After 3 Doses Metastatic NET Pancreas with Adrenal Crisis Tumor Before Treatment Tumor After 3 Doses (S.ACTH)!- 790 pg/ml
Slide 21: Clinical Investigation of VMT-α-NET in Metastatic SSTR2 Positive Patients
Clinical Investigation of [!2Pb]VMT-c-NET in Metastatic SSTR2 Positive Patients Interim Results as of September 28, 2023. for Ongoing Investigationin India current status + Patients with prior lines of therapy. late-stage, anatomically sey Tsing? tienen NETe (ran as: 4 yours fea). + Nosignicantrenal
Slide 22: High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs
High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs Interim Results as of September 28, 2023, for Ongoing Clinical Investigation Program in India me Ok Patents ox ak © reer eee ak Patents ex ex? races Kener ek Ok > res ext Ok raven? a > apes) a Ca > Sarre, ve Kener Ok
Slide 23: Trial Design: VMT-α-NET Phase 1/2a For Neuroendocrine Tumors
Trial Design: [2“2Pb]VMT-o-NET mTPI-2! Phase 1/2a For Neuroendocrine Tumors PrimaryObjectve: To determine the MTO/MFO of #PD]VMTa-NET(RP2D)| Imaging, FOA approved SSTR2 PET/CT 25-10 mCi dose escalation with fed dosing every Escalation n = 10:32 Therapeutic Dose: = Expansion = 20 ~ 100 B weeks for up
Slide 24: Melanoma Program: VMT01/02
Melanoma Program: VMT01/02 Using the melanocortin receptor MC1R to target melanoma for imaging and therapy
Slide 25: Slide 25
Slide 26: Metastatic Melanoma
Metastatic Melanoma [2*2Pb]VMTO1 target indication: MCAR-positive melanoma + Projected market opportunity for melanoma of $8 billion in 2028* + Significant unmet needin the US . # ver + 100K new diagnoses annually? + ~8,000 people die from melanoma every year? + Treatment depends on the stage of tum
Slide 27: [68Ga]VMT02 PET Imaging in Patient with MC1R Positive Metastatic Melanoma
[®Ga]VMT02 PET Imaging in Patient with MC1R Positive Metastatic Melanoma Diagnostic Peptide DemonstratesSimilar Uptake to FDG in Tumors 38F-FDG (Standard of Care) [esGajvmr02 Patient information: + Male, Asian, 33 years old + [68Ga]VMTO2: 7 mci injection, 45 min post- injection imaging Clinical Coll
Slide 28: (A) Perspective
(A) Perspective
Slide 29: [212Pb]VMT01 in Combination Demonstrates Synergistic Responses
[22Pb]VMTO1 in Combination Demonstrates Synergistic Responses Multiple Melanoma Tumor Models Show Promise of Combining with Standard of Care Key Takeaways + High response rates in multiple tested models + 43% complete and durable response if combined with immunotherapy in.a model highly resistant to
Slide 30: Trial Design: VMT01-T104 Phase 1/2a For Metastatic Melanoma
Trial Design: [2“2Pb]VMT01-T104 mTPI1 Phase 1/2a For MetastaticMelanoma PrimaryObjpetve: To determine the NTO/MFO of [PDVNTOA (RP2D) Imagine (ppyvMTOL SPEG/CT or (*GayvatTOR PET/CT a 3 ~ 15 m0 dose escalation with xed dosing every 8 ‘Screen ~120 subjects Lemenctams weeks for upto 3 cycles Population
Slide 31: Prostate Cancer Program: PSV401
Prostate Cancer Program: PSV401 A differentiated PSMA-targeted radiohybrid molecule for dual PET imaging and targeted alpha therapy
Slide 32: Prostate Cancer Program: PSV401
Prostate Cancer Program: PSV401 differentiated PSMA-targeted radiohybrid molecule for dual PET imaging and targeted alpha therapy PSMA is a clinically and commercially validated target for 4 a radioligand therapy Combines two chelators al distribution of ith single targeting ligand to provide aging
Slide 33: Pre-Targeting Platform
Pre-Targeting Platform The Next Generation of Targeted Alpha Particle Radiopharmaceuticals
Slide 34: Pre-Targeting Platform Background
Pre-Targeting Platform Background Relies on the differentkinetics of large proteinsand small moleculesand a multistep process © rirnstr cota moated monotona rthoy or ageing oti @© 112° sever cas. man witnave acount on nor and lead rom Hood © Aainisterraciotaveted tigana, which binds specifically to
Slide 35: Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics
Manufacturing, Production and Logistics of 7127Pb- labeled Therapeutics The Path to Commercial Supply
Slide 36: 212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics
212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics The supply chain is lowerriskand more robust than other therapeuticisotopes Isotope Purification Product Manufacturing, Naturally occurring in mining waste Parentsotope Thorium-228 can be VMFaGEN 22Po generator technology sc
Slide 37: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurringlsotope Decay - No Irradiation Processes Required Plentiful Supply: Naturally occurring, or produced as a waste product Chemical Separation: ‘Allows for Ra-based. generatorsof Pb Chemical Separation from
Slide 38: 212Pb Isotope Purification Without Just-in-time Irradiation
212Pb Isotope Purification Without Justin-time Irradiation ‘Simple chemical separation technology of natural decay products de-risks supply chain Inlet >———Solvent B Cc Chromatography Immobilized ‘Accumulation Retention column - 22tRa - of 22pb - of 24a - entioeaeTt produces 2!°Pb naturally “Stays o
Slide 39: 212Pb Supply via Reusable Desktop Isotope Generator
212Pb Supply via Reusable Desktop Isotope Generator VMT-a-GEN + Extensive feedstock from nuclear and mining waste material + Longterm supply contract secured with US DOE + On demand daily doses — Auto-regenerates overnight ~ ~Lweek shef life ‘Small, Elegant 42Pb Isotope Generator + Integrated lead s
Slide 40: Scalable Manufacturing and Distribution Logistics
Scalable Manufacturing and Distribution Logistics Perspective'splan to flexibly scale manufacturingto commercial levels (100,000+ doses per year) (GenertorManuenrce cme im manufactures — Senerator andshippea | eteat tocowe Rago-stness ware Modu generator Stesinnouse ‘como Dispensing Detvery samisrat
Slide 41: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurring lsotope Decay ~ No Irradiation Processes Required + Certs continental supply + Eluted week for Ra + Distributed continentaly + eluted day for2P0, + Daily manufacture of finshed doses + Leverages existing
Slide 42: Infrastructure and Distribution Networks for Radiopharmaceuticals are Mature
Infrastructure and Distribution Networks for Radiopharmaceuticals are Mature Existing radiopharmacies have established logistics for distributed supply ‘Map of US Radiopharmacies* + There were 40+ million diagnostic nuclear medicine procedures performed in the US in in 2022 + Multiple networks exist
Slide 43: Regional Manufacturing Allows Commercialization of 212Pb-labeled Finished Products
Regional Manufacturing Allows Commercialization of “2Pb-labeled Finished Products Limited number of sites allows for “network effect” to ensure robustsupply chain nil Coralville. 8 sim New York. NY 75m Los Angeles, CA 46m Austin, 1X 32m ‘ilanta, GA stm Centra Florida, FL 25m Proposed or esi ‘Top 6 s
Slide 44: Strong Intellectual Property Portfolio
Strong Intellectual Property Portfolio Fully Licensed University/Perspective-owned IP 4 provisional patents * Composition of Matter and Use radiometal separations technology, novel pan-cancer product . generator technologies (US., EU. Australia) 3 non-provisional patent applications. + Composition o
Slide 45: Appendix
Appendix
Slide 46: Treating cancer from the inside out
Treating cancer from the inside out We are developing game-changing Precision Medicine Therapeutics which harness the power of targeted Alpha-Particle Radiotherapies that make an impactful difference for cancer patients and the clinicians Who treat them.
Slide 47: Who We Are
Who We Are ‘Perspective Therapeutics (NYSE:CAD))'s a clinical stage precision medicine company, debuting as a public company in 2023. \With a broad pipeline and two prioritized lead programsin cnic, we are disrupting traditional radiation therapy treatment for cancer though developing new class of i
Slide 48: α-Particles Have Superior Tumor Killing Properties vs. β-Particles
a-Particles Have Superior Tumor Killing Properties vs. B-Particles More Powerful Effects Than ‘Approved B Therapy Precision Delivery Provides Targeted Cell Destruction Antitumor Response Higher atomic mass Lethal double-stranded DNA breaks DNA repair mechanisms overwhelmed Deposit energy over 3-5 ce
Slide 49: Lead-212: The Optimal Therapeutic Isotope
Lead-212 (2#2Pb): The Optimal Therapeutic Isotope Greater Therapeutic Energy Expected to Improve Outcome with Better Safety Alpha particle range (up to 3 cell diameters) Beta range (up to 200 cell diameters) Tumor Celis Normal Tissue oa, : ’ ame amm 0mm Tumor Healthy tissue ter oT A) pessererve
Slide 50: Lead (Pb): The Ideal Theranostic Isotope
Lead (Pb): The Ideal Theranostic Isotope Ideal Theranostic Requirements {deal agreement between imaging and therapeutic compounds Readily available isotope Ideal chelator Rapid clearance from blood High tumor retention @24 hours. ‘Short t-¥2 gives rapid effect while minimizing environmental impact '
Slide 51: Peptides are Ideal Ligands for Radiopharmaceutical Therapy
Peptides are Ideal Ligands for Radiopharmaceutical Therapy Monoclonal antibodies eptides Tweens: | tow Manusctunng | Canon bloga Tune penmatae: | Hen Manwtacturne | Srinae arn vepacouary oer | | co Hen ware: Renate) | | exe veoiow Belogea te | Long Bovogeal se | Stor Taree atiny | Hn Target ateny |
Slide 52: VMT-α-NET is Developed to Address the Unmet Need in NETs
VMT-a-NET is Developed to Address the Unmet Need in NETs CurrentStandard of Care limited to subset of NETs patients NETTER Sty Fnaloveral svat Significant unmet need . + ~12K new diagnoses annually in the US* parental + ~175,000+ people are living with this diagnosis in the US* nated RO 958006017 bk
Slide 53: 225Ac Isotope Decay Chain and Potential for Off-Target Toxicity
225Ac Isotope Decay Chain and Potential for Off-Target Toxicity ‘a Alpha-particle emission OH oreo ak chia = bonds "amend ‘Aypn01 ero soERuEIeG
Slide 54: Isotope: Decay chain - Product implications
Isotope: Decay chain - Product implications Postfinal radiolabelingand purification, alpha and beta emittingdaughters of 7°Ac build up fast ‘and Daught MAC225 wFr221 mAL2IT mBL213 = T1209 mPo213 000 |__ 4 more unabeted daugter activin about 4 ns = 5000 2 4000 3 2000 = 2000 1000 ° 0 4 2 g 4 5 Hours P
Slide 55: 212Pb Isotope Decay Chain and Importance of the Pb-Specific Chelator
212Pb Isotope Decay Chain and Importance of the Pb-Specific Chelator 2 | 2 @ ‘Where the drug goes = where the alpha particle is deposited ° OH + Perspective's proprietary chelator retains 98% of 2428) after transition in drug formulation + Generic chetatorsleak the #Bi alpha-emitting daughter up to
Slide 56: Clinical Advisors
GeotfreyB. Johnson MD.PhD RE (Chair, Dision of Nuclear Medicine hair, PET/MRREO Associate Professor Departments of Radiology ‘and Immunology Mayo Gini ~ Rochester, MN Vikas Prasad MD Professor of Radiology bay Associate Professor Radiology Dison of Nuclear Medicine Washington University in St Lous -
Slide 57: Appendix: VMT-α-NET
Appendix: VMT-o-NET
Slide 58: Significant Tumor Response After Two Doses
Significant Tumor Response After Two Doses Patient 3: Metastatic NET Pancreas with Liver Metastases MIP image Before Treatment MIP image After 2nd Treatment bg | Liver Metastases after treatment with two doses
Slide 59: Reduction in Size of Necrotic Masses After Doses
Reduction in Size of Necrotic Masses After 2 Doses Patient5: Pancreatic NET Tumor Before Treatment Tumor After Treatment
Slide 60: Favorable Safety and Tolerability Profile
Favorable Safety and Tolerability Profile FourMonths Post Treatment(5 Patients) Hemoglobin Levels Total Leukocyte Count re ——— rr | : Fae amonisy © . . aaa nonsy ‘
Slide 61: Serious Adverse Event in Patient
Serious Adverse Event in Patient 2 Myelodysplastic syndrome (MDS) Unrelated to Study Drug Patient Profile + 79 year-male at an interval of 8 weeks (Cumulative dose 9.6 mCi) e + Shows Partial response for disease till date. + Metastatic Medullary Carcinoma thyroid + Disease progression of TKI's |<) +
Slide 62: Serious Adverse Event in Patient
Serious Adverse Eventin Patient 6 Acute Cardiac Event Unrelated to Study Drug Significanttumor burden Patient Profile 25 yearmale Metastatic NET-pancreas Longsstanding disease (>6 years duration) Heavily pre-treated with Inj. Sandostatin and 4 cycles of *77Lu- DOTATATE along with CAPTEM regimen Rece
Slide 63: Appendix: Prostate Cancer Program - PSV401
Appendix: Prostate Cancer Program - PSV401
Slide 64: Typical Theranostic Approach: One Molecule, One Chelator, One Isotope
Typical Theranostic Approach : One Molecule, One Chelator, One Isotope ‘Separate But Chemically identical Molecules Labeled with Either2™Pb or 2!2Pb for Imaging and Treatment, Respectively Imaging Note: — One chetator 2A hours Cancer Cell 29h ‘One isotope Patient selection t Dosimetry: T, , = 52h Tw
Slide 65: PSV401 DoubLET: One Molecule, Two Chelators, Four Possible Isotopes
PSV401 DoubLET*?: One Molecule, Two Chelators, Four Possible Isotopes (One Molecule Labelled with Two Elementsat Once. with Isotope Selection Determining Diagnosticor Therapeutic Two chelators on one targeting ligand s Each can be labeled with stable or radioactive atoms eusrmatgy Enables the same m
Slide 66: PSV401 Has Potential to be Best-In-Class Prostate Cancer Targeted Alpha Therapy
PSV401 Has Potential to be “Best-In-Class” Prostate Cancer Targeted Alpha Therapy CurrentStandard of Care with Beta-Based Radiopharmaceutical Therapy (RPT) Still Requires improvement Significant Unmet Need: ~288K newdiagnoses annually in the US* ~3.3M+ menliving with this diagnosis in the US* ~35K d
Slide 67: PSV401: Preclinical Cu PET Imaging Data Showing Tumor Uptake
PSV401: Preclinical Cu PET Imaging Data Showing Tumor Uptake Rapid Tumor Uptake and Effective Renal Clearance with Radioactive Imaging |sotope* Key Takeaways PSMA+ LNCaP tumor 15 min p.i. 30 min p.i. 60 min p.i model suggests {®Cu]PSv401 targets Coronal Sagittal Coronal Sagittal Coronal Sagittal Cor
Slide 68: PSV401: Preclinical Comparison to Industry Standard
PSV401: Preclinical Comparison to Industry Standard* 'Cu]PSV401. Compares Favorably to FDA-Approved Imaging Agent [Ga]PSMA-11 (ILLUCCIX®, Telix)? 15 min p.i. 30 min pai 60 min pi. 120 min pi. Coronal Sagittal Coronal “Sagittal ‘Coronal ‘Sagittal Coronal Sagittal Coronal suv. R Coronal Sagittal Coron
Slide 69: PSV401: Preclinical Comparison to Industry Standard
PSV401: Preclinical Comparison to Industry Standard (*Cu]PSV401 Significantly" Improved Uptake/ Clearance Compared to [“Ga]PSMA-11? ‘Tumor Retention Kidney Retention Salivary Gland Retention a (oapswast foupsvecs = foopsinas a“) « oupsveo 3 2) 0, = moursor 3? = 21) 3 5 ‘ $ ae ~ pop 2 a Bus 3 T (reup
Slide 70: Preclinical [212Pb]PSV401 Therapy
Preclinical [7“2Pb]PSV401 Therapy Preliminary [2"2Pb]PSV401 Data Shows Potentialto Effectively Kill Tumors + + Allimaging performed with [“Cu]PSV401 microPET + Treatment of PSMA+ prostate cancer xenograft with [22Pb]PSV401 reduced tumor size 38% in 3 days and complete response after 9 days * Additio
Slide 71: Appendix: Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics
Appendix: Manufacturing, Production and Logistics of 212Pb-abeled Therapeutics
Slide 72: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurring Isotope Decay - No Irradiation Processes Required Plentiful Supply: Naturally occurring. or produced as a waste product, Chemical Separation: ‘Allows for Ra-based ‘generators of Pb, Chemical Separation f
Slide 73: Parent Isotope Source
Parent Isotope Source Key|sotopes for Supply:2°ThandRa 228Th hallf-ife of 1.9 years allows long term storage and extraction of daughter 2Ra 224Ra grows in naturally (without irradiation) from 228Th decay Perspective currently has a 10 year supply agreement with US Department of Energy Produced as a
Slide 74: Flexible and Scalable Isotope Supply
Flexible and Scalable Isotope Supply 224Ra enables Regional Manufacturing Hubs 224Ra halflife of 3.6 days allows weekly shipments to regional manufacturing sites 232P} grows in naturally (without irradiation) from Ra decay Perspective's proprietary VMFa-GEN enables shipping of isotope and purficatio
Slide 75: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurring|sotope Decay - No Irradiation Processes Required + Cental continental supply + Eluted week for Ra + Distributed continentaly + eluted dai forP0, + Daily manufacture of fished doses + Leverages existing n
Slide 76: 212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics
212Ph is Plentiful, Storable, Scalable & Suitable for Distributed Logistics The supply chainis lowerriskand more robustthan other therapeuticisotopes Isotope Purification Product Manufacturing, Naturally occurring in mining waste Parentsotope Thorium-228 can be VMFaGEN 22Po generator technology scal
Slide 77: Parent Isotope Source
Parent Isotope Source + Storage of thorium-228 (halflife of 1.9 years) allows for “on-demand” purification of Ra-224 and Pb-212 + Multiple purfication/production methods for Th-228 with different starting materials and processes, including Ra-228 generators (half- life 5.7 years) + Ra-224 (half-life
Slide 78: Parent Isotope Supply
Parent Isotope Supply + Thorium-228 is available as a natural isotope buts also producedas a waste product from the nuclear fuel cycle. and as a result of production of therapeuticisotope Ra-223 (marketed as Xofigo, Bayer) + Both Ac-227 (the parent isotope of Ra-223) and Th-228 are created \when DOE
Slide 79: Pb-212 Isotope Purification
Pb-212 Isotope Purification ‘+ Similar in size to Ga-68 generators ‘+ Useful for prectinical R&D and clinical trials, ‘+ Nimble. portable supply available for ether, local or regional production Typically chromatography column based Using Ra-224 as parent Shetflife approx. 1-2 weeks 41-2 doses per b
Slide 80: 212Pb Supply via Reusable Desktop Isotope Generator
212Pb Supply via Reusable Desktop Isotope Generator VMT-a-GEN + Extensive feedstock from nuclear and mining waste material + Longterm supply contract secured with US DOE + On demand daily doses — Auto-regenerates overnight ~ ~Lweek shef life ‘Small, Elegant 42Pb Isotope Generator + Integrated lead s
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Slide 85: Slide 85
Slide 86: Slide 86
Slide 87: Slide 87
Perspective Therapeutics — Investor Presentation (March 2024) on 6ix